

JAN-25-07

11:26AM FROM-

T-704 P.001/003 F-761



Pioneering Medicines
for a Better Life™

RECEIVED
CENTRAL FAX CENTER
JAN 25 2007

Kos Pharmaceuticals, Inc.
1 Cedar Brook Drive
Cranbury, NJ 08512
LEGAL DEPARTMENT
Fax: (609) 495-0907
www.kospharm.com

FACSIMILE TRANSMITTAL SHEET

TO:	FROM:
USPTO	Oscar Espinoza
COMPANY:	DATE:
	01/25/2006
FAX NUMBER:	TOTAL NO. OF PAGES INCLUDING COVER:
(571)273-8300	3
NOTES/COMMENTS:	

CONFIDENTIAL

The information contained in this facsimile is privileged and confidential and is intended only for the use of the individual(s) named above. If the reader of this facsimile is not the intended recipient, or the employer or agent responsible for delivery of this facsimile to the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this communication is neither intended nor permissible. If you have received this facsimile in error, please immediately notify us at the above telephone number or send an email message to the above sender and kindly delete this message. Thank you.

JAN 25 2007

BEST AVAILABLE COPY

PTO/SQ/81 (01-06)

Approved for use through 12/31/2008. OMB 0851-0038
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10/085,059
Filing Date	2/27/2002
First Named Inventor	Rocca
Title	A Sustained Release Pharmaceutical
Art Unit	1817
Examiner Name	Leonard Williams
Attorney Docket Number	SD-20003

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☐ Practitioners associated with the Customer Number:

OR

☒ Practitioner(s) named below:

Name	Registration Number
Jonathan M. Provost	44,292
Karen P. Bechtold	52,168

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☒ Firm or Individual Name Kos Pharmaceuticals, Inc.

Address 1 Cedar Brook Drive

City Cranbury

State NJ

Zip 08512

Country USA

Telephone 609-485-0500

Email jprovost@kospharm.com

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/06)

SIGNATURE of Applicant or Assignee of Record

Signature

Date

2/4/2007

Name

Mark McGovern

Telephone

854-331-3400

Title and Company President, Kos Life Sciences, Inc.

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JAN-25-07 11:27AM FROM-
Jan 24 07 01:56p Mark McGovern

RECEIVED
CENTRAL FAX CENTER

T-704 P.003/003 F-761

JAN 25 2007

BEST AVAILABLE COPY

PTO/SB/90 (09-08)

Approved for use through 03/31/2007. OM9 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Kos Life Sciences, Inc.

Application No./Patent No.: 10086059 Filed/Issue Date: 2/27/2002

Entitled: A Sustained Release Pharmaceutical Formulation

Kos Life Sciences, Inc.
(Name of Assignee)

Delaware Corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Jose Gutierrez-Rocca To: Kos Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 014607, Frame uwr, or for which a copy thereof is attached.

2. From: Josephine Dunne To: Kos Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 014607, Frame uwr, or for which a copy thereof is attached.

3. From: Kos Pharmaceuticals, Inc. To: Kos Life Sciences, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Mark McGovern
Signature

24 January 2007
Date

Mark McGovern

Printed or Typed Name

954-331-3400

Telephone Number

President
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.